மேம்படுத்துகிறது உலகளாவிய News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மேம்படுத்துகிறது உலகளாவிய. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மேம்படுத்துகிறது உலகளாவிய Today - Breaking & Trending Today

Analog Devices and MDA Collaborate to Provide Electronic Beam Forming Technology for the Telesat Lightspeed Constellation, Enhancing Global Connectivity


Contact
Linda Kincaid
Global PR Manager
Analog Devices and MDA Collaborate to Provide Electronic Beam Forming Technology for the Telesat Lightspeed Constellation, Enhancing Global Connectivity
Apr 7 2021 -Wilmington, MA
Analog Devices, Inc. (Nasdaq: ADI) announced today a collaboration with MDA to deliver the beam forming integrated circuit (BFIC) to be used in MDA’s sophisticated phased array antenna for the Telesat Lightspeed low earth orbit (LEO) satellite constellation. Telesat Lightspeed, initially comprised of 298 next-generation satellites, is planned to launch in the second half of 2023 and will redefine global broadband connectivity for commercial, government, and defense markets.
LEO satellites, rather than operating from a fixed position, move across the sky and must dynamically steer communication beams to maintain uninterrupted and high-speed connectivity to ground ter ....

United Kingdom , Bryan Goldstein , Telesat Lightspeed , Samer Khouri , Analog Devices , Analog Devices Inc , Provide Electronic Beam Forming Technology , Telesat Lightspeed Constellation , Enhancing Global , Vice President , Satellite Systems , ஒன்றுபட்டது கிஂக்டம் , பிரையன் கோல்ட்ஸ்டைன் , அமர் கௌரி , அனலாக் சாதனங்கள் , அனலாக் சாதனங்கள் இன்க் , வழங்க மின்னணு உத்திரம் உருவாக்கும் தொழில்நுட்பம் , மேம்படுத்துகிறது உலகளாவிய , துணை ப்ரெஸிடெஂட் , செயற்கைக்கோள் அமைப்புகள் ,

Novartis investigational oral therapy iptacopan (LNP023) receives FDA Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation for C3G


Posted December 16th, 2020 for Novartis
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening blood disorder, resulting in debilitating symptoms that can impact patients’ quality of life
1–3
C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need
4-5
With potential to be the first oral treatment for a range of complement-driven diseases, complement factor B inhibitor iptacopan targets the underlying cause of these conditions through its action on the complement system’s alternative pathway
6,7
Iptacopan is in development for PNH, as well as C3G and several other rare renal diseases including IgA nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and membranous nephropathy (MN); first FDA filings anticipated in 2023 ....

United States , Eric Althoff , Isabella Zinck , Samir Shah , Thomas Hungerbuehler , Phil Mcnamara , Sloan Simpson , Nephrol Hypertens , Drug Administration , Novartis Oncology Communications , International Paroxysmal Nocturnal Hemoglobinuria Registry , Novartis Us External Communications , Exchange Commission , European Society For Blood , Meeting Of The American Society Nephrology , Metabolic Communications , European Medicines Agency , Breakthrough Therapy Designation , Rare Pediatric Disease , European Society , Marrow Transplantation , American Society , International Paroxysmal Nocturnal Hemoglobinuria , Accessed September , Improving Global , Accessed December ,